|Home | About | Journals | Submit | Contact Us | Français|
During the inflammatory response that drives atherogenesis, macrophages accumulate progressively in the expanding arterial wall1,2. The observation that circulating monocytes give rise to lesional macrophages3–9 has reinforced the concept that monocyte infiltration dictates macrophage build-up. Recent work indicates, however, that macrophages do not depend on monocytes in some inflammatory contexts10. We therefore revisited the mechanism of macrophage accumulation in atherosclerosis. We show that murine atherosclerotic lesions experience a surprisingly rapid, 4-week, cell turnover. Replenishment of macrophages in these experimental atheromata depends predominantly on local macrophage proliferation rather than monocyte influx. The microenvironment orchestrates macrophage proliferation via the involvement of scavenger receptor (SR)-A. Our study reveals macrophage proliferation as a key event in atherosclerosis and identifies macrophage self-renewal as a therapeutic target for cardiovascular disease.
Over the last 30 years macrophages have emerged as protagonists of atherosclerosis and its complications. Macrophages amass in lesions, ingest lipids, and produce a diverse repertoire of inflammatory mediators that exacerbate disease1,2. In the mouse, lesional macrophages arise predominantly from circulating Ly-6Chigh monocytes5–7,11–13. These insights have contributed to the perception that macrophages gradually accrue in atherosclerotic lesions whereby a single infiltrating monocyte yields one terminally-differentiated macrophage. Recent observations that monocyte kinetics in acute injury are rapid14, that tissue macrophages may not depend on monocytes10,15, and that the adventitia harbors hematopoietic progenitors16 reveal potential alternative explanations for how atherosclerosis evolves. The prevailing models, therefore, require reevaluation.
Do lesional macrophages in atherosclerosis accumulate gradually or turn over rapidly? To answer, we subcutaneously implanted osmotic pumps containing the thymidine analogue 5-bromo-2′-deoxyuridine (BrdU) in 4-month old apolipoprotein E-deficient (Apoe−/−) mice consuming a high cholesterol diet (HCD) for 8 weeks. BrdU incorporates into newly synthesized DNA and thus reports on a cell’s, or its progenitor’s, proliferative history. Nearly all (92±1%) aortic macrophages, identified as Lin− CD11b+CD11clow-negF480high cells by flow cytometry (Fig. 1a), stained for BrdU after 4 weeks (when mice were 5 months old) (Fig. 1b and c). Immunofluorescence experiments identified Mac3+BrdU+ macrophages within the plaque intima and adventitia (Fig. 1d–f). This low-level BrdU administration had no intrinsic effect on macrophage turnover kinetics because the rate of BrdU signal decay following pump removal closely approximated its rate of incorporation (Fig. 1c). Despite observed increases in lesion size (Fig. 1g), aortic root macrophage burden did not change significantly during BrdU labeling (Fig. 1h), suggesting that, at this stage of atherosclerosis, cell loss processes counterbalance macrophage renewal. These data identify a previously unrecognized dynamic in the mononuclear phagocytic response during atherosclerosis and reveal remarkably rapid macrophage turnover in lesions.
Lesional macrophages could replenish either through the continuous recruitment of circulating monocytes or through some other processes. We assessed lesional macrophage accumulation in Apoe−/− HCD mice depleted of circulating monocytes for 5 d (Fig. 2a) and found, unexpectedly, that monocyte depletion had no effect, not only on incorporation of BrdU by lesional macrophages (Fig. 2b and c) but also on the number of total macrophages (Fig. 2d) and total lesion area (Supplementary Fig. 1a). To examine the relationship between blood monocytes and tissue macrophages in more detail, 4-month old CD45.1+ Apoe−/− HCD and CD45.2+ Apoe−/−HCD mice (8 weeks of Western diet) were joined for 5 weeks by parabiosis, a procedure that allows circulating cells to enter partner tissues17. The procedure did not alter the frequency of monocytes in the blood (Supplementary Fig. 1b) and had no effect on BrdU incorporation in lesional macrophages (Supplementary Fig. 1c). Whereas Ly-6Chigh monocyte chimerism in the blood (30±5%), spleen (26±4%), and aorta (25±6%) was high – and typical of monocyte chimerism at equilibrium18 – macrophage chimerism in the aorta was low (5±2%) (Fig. 2e–g). Therefore, in established disease, the discrepancy between monocyte and macrophage chimerism illustrates either slow macrophage replenishment or macrophage replenishment that does not rely exclusively on monocyte influx. Because macrophages replenish rapidly in established disease (~4 weeks, Fig. 1), macrophage accumulation likely occurs through processes other than monocyte infiltration. Surgical separation of parabionts provided complementary evidence in support of this conclusion. Separation led to a decline in monocyte chimerism in blood, spleen and aorta, but chimerism among lesional macrophages remained unchanged for at least 2 weeks (Fig. 2h). Together, these data show that monocyte recruitment cannot fully account for lesional macrophage accumulation in established atherosclerosis.
Macrophage turnover that is largely independent of monocytes does not preclude the initial development of plaque macrophages from hematopoietic precursors. To determine when monocytes and macrophages converge, relatively young (early atherosclerosis) mice were joined in parabiosis for 1 and 4 weeks. Unlike established disease (Fig. 2e–g), monocyte and macrophage chimerism in these mice was similar (Supplementary Figure 2a), which is aligned with previous observations that early development of atherosclerotic lesions depends on monocyte recruitment19. To determine if monocytes and macrophages converge in established disease, we lethally irradiated and reconstituted 4-month old CD45.2+Apoe−/− HCD mice with bone marrow from CD45.1+Apoe−/− mice. Over 5 months, lesional macrophages in these animals with established plaques were eventually replenished by donor-derived CD45.1+ cells (Supplementary Fig. 2b). These data suggest that, even though rapid lesional macrophage turnover does not require constant monocyte influx, aortic macrophages ultimately derive from a circulating precursor.
The recent identification of hematopoietic progenitors in the aortic adventitia16 raised the possibility that lesional macrophages arise from circulating intima-seeded multipotent hematopoietic stem and progenitor cells (HSPC). To address this, we performed granulocyte-macrophage colony forming experiments on aortic tissue. As shown previously11, HSPC were highly active in the bone marrow and spleen of Apoe−/− HCD mice (Fig. 3a). The entire aorta, on the other hand, yielded no more than 2 macrophage colonies per animal. These data accord with the recent study on HSPC activity in the vascular wall16, and indicate that local hematopoiesis of a multiproliferative progenitor contributes minimally to lesional macrophage accumulation in atherosclerosis.
Macrophage proliferation in atherosclerotic lesions has been identified in humans, rabbits and mice20–26 but its importance relative to monocyte recruitment has not been evaluated. We addressed this by several independent and complementary approaches. First, we adoptively transferred Ly-6Chigh monocytes from GFP+ mice to Apoe−/− mice consuming HCD. 24 h following transfer, we also injected BrdU to track proliferation. 2 d after BrdU pulse, non-proliferating BrdU−GFP+ monocytes were detected in the recipient blood (Fig. 3b). In the aorta, GFP+ cells grouped into F480low BrdU− cells, representing a few monocytes that had accumulated but neither differentiated nor proliferated, and F480high cells, representing monocyte-derived macrophages, some of which had proliferated locally (BrdU+) (Fig. 3b). The data indicate that proliferating lesional macrophages derive from non-proliferating circulating monocytes. Future studies will need to determine whether lesion-infiltrating monocytes, in addition to differentiation, die locally or exit. Second, we performed a 2 h in vivo BrdU-pulse labeling experiment, used previously to detect neointimal dendritic cell proliferation19. At a time when circulating monocytes had not yet incorporated BrdU (Supplementary Fig. 3a), macrophages in both Apoe−/− (Fig. 3c) and Low Density Lipoprotein Receptor-deficient (Ldlr−/−) (Supplementary Fig. 3b) mice were already BrdU+, indicating local proliferation. Third, analysis of the S and G2/M phases of the cell cycle using the intercalating dye 4′,6-diamidino-2-phenylindole (DAPI) revealed a high percentage of proliferating aortic macrophages in Apoe−/−mice consuming a high cholesterol diet (Fig. 3d). This finding contrasted with macrophages from wild type (WT) and young (2 month old) chow-fed Apoe−/− mice, which proliferated less, and monocytes, which did not proliferate under any circumstances (Fig. 3b, d, e). Fourth, positive staining of gated G2/M-phase lesional macrophages for phospho-histone H3 confirmed mitosis (Fig. 3f). Fifth, to directly visualize cell division, we utilized the ImageStreamX™ Mark II platform, an approach that links multi-parameter flow cytometry with single cell immuno-fluorescence imaging. Analysis of Apoe−/− HCD mice showed G2/M-phase aortic macrophages in various phases of mitosis (Fig. 3g). Sixth, immunofluorescence of aortic root sections showed numerous intimal Mac3+ macrophages staining positive for the nuclear proliferation antigen Ki67 (Fig. 3h). The key to interpreting these last four experiments is the ability of DAPI, phospho-histone H3, and Ki67 to identify currently – rather than formerly – proliferating cells. The colocalization of markers of cell division with mature macrophage markers (F480 by flow cytometry and Mac3 by immunofluorescence) indicates that lesional macrophages proliferate. Finally, immunohistochemistry of atherosclerotic plaques from human carotid arteries revealed Ki67-expressing oil red O+ and CD68+ lesional macrophages (Supplementary Fig. 3c), indicating that in situ proliferation of mature intimal macrophages occurs in experimental and human atherosclerosis. While classic studies have shown that the dominant proliferative cell type in the human intima is the monocyte/macrophage in both early23 and advanced atherosclerosis21,22, it remains to be determined whether local macrophage proliferation contributes substantially to human lesion growth, turnover, and rupture.
To quantify the contribution of local proliferation to macrophage accumulation in established atherosclerotic lesions, 4 month-old CD45.1+ Apoe−/− HCD and CD45.2+ Apoe−/− HCD (8 weeks on diet) mice were joined by parabiosis and implanted with BrdU-containing osmotic pumps for 4 weeks (Fig. 3i). This experiment allowed assessment of macrophage chimerism exclusively in newly accumulating BrdU+ macrophages. Among newly accumulating macrophages in CD45.1+ aortas, only 4% were CD45.2+ (Fig. 3i), which agrees with our previous observations and further argues against macrophage residential longevity as the determining factor for low chimerism (Fig. 2e and f). Aortic chimerism alone underestimates the overall contribution of circulating monocytes because monocyte chimerism in the blood, even at equilibrium, is only ~30% (Fig. 3i). Therefore, assuming that individual CD45.1+ and CD45.2+ cells can infiltrate lesions equally, for every partner-derived (i.e., CD45.2+) monocyte that entered the CD45.1+ aorta, ~2 endogenous (i.e., CD45.1+) monocytes also entered. Hence, the total contribution of the circulation (CD45.1+ and CD45.2+) to macrophage accumulation in a 4-week period in established disease can be, at most, ~13% (Fig. 3j). Local proliferation, which accounts for the remaining ~87% of newly-labeled BrdU+ macrophages, dominates macrophage accumulation in established atherosclerosis (Fig. 3j). Similar studies conducted during early atherosclerosis, when lesional macrophage burden was still minimal (Supplementary Fig. 2a), demonstrated a larger contribution of recruited monocytes to macrophage accumulation (Fig. 3j). Collectively, these data show that, as atherosclerosis progresses, macrophage turnover becomes increasingly dependent on local proliferation of lesional macrophages.
Since lesional macrophages reside in a tissue context, macrophage proliferation might depend on the local microenvironment. We addressed this possibility with several approaches. First, we joined 4 month-old WT (C57BL6/J, CD45.1+) and Apoe−/−(CD45.2+) HCD mice by parabiosis. The joined heterogenic partners consumed a high cholesterol diet for 5 weeks. During this period, atherosclerotic lesions persisted in Apoe−/− partners but did not develop in WT partners. Among the cells accumulating in aortas, lesional macrophage chimerism remained low (Fig. 4a), although the WT aorta contained fewer total cells. Whatever the cell’s origin (host or partner, Apoe−/− or WT) macrophages accumulating in Apoe−/− mice were more likely to proliferate compared to macrophages accumulating in WT mice (Fig. 4a and b). We also assessed macrophage proliferation in Apoe−/− HCD mice in different aortic segments of the same animal. Proliferation was highest among macrophages located in the aortic root and arch (where lesions are most abundant), intermediate among macrophages located in the thoracic aorta (intermediate abundance), and lowest in the abdominal aorta (least abundance) (Supplementary Fig. 4). To discriminate between lesional and adventitial macrophage proliferation, the intima was separated from the vessel wall, as previously described27. Whereas adventitial macrophages proliferated at a rate similar to that observed in young non-atherosclerotic mice, lesional macrophages proliferated at a high rate (Fig. 4c). Thus, the microenvironment influences macrophage proliferation.
By what mechanism are lesional macrophages proliferating? Neither neutralizing antibody nor genetic studies targeting GM-CSF affected macrophage proliferation (Supplementary Fig. 5a and b), which was somewhat surprising given the growth factor’s known role in macrophage differentiation and neointimal DC proliferation19. We turned our attention to the type 1 scavenger receptor class A (SR-A, also known as Msr1), which is expressed on lesional macrophages28,29, recognizes modified low-density lipoproteins30, and correlates with macrophage proliferation31. We generated mixed chimeric mice by irradiating and reconstituting Ldlr−/− mice with a mixture of WT CD45.1+ and Msr1−/− CD45.2+ bone marrow cells (Fig. 4d). This approach allowed us to compare proliferation of Msr1-competent and deficient macrophages in the same lesional microenvironment. After 16 wk of HCD, bone marrow transplantation was associated with engraftment and circulation of moderately fewer Msr1−/−CD45.2+ monocytes compared to WT CD45.1+ monocytes (Supplementary Fig. 5c). In the aorta, we observed ~60% fewer Msr1−/−CD45.2+ macrophages compared to WT CD45.1+ cells (Supplementary Fig. 5d) When animals were pulsed with BrdU for 2h, circulating monocytes were almost entirely BrdU− regardless of genotype (Fig. 4e). Compared to WT cells, Msr1−/− macrophages proliferated less (Fig. 4f) and BrdU+ Msr1−/− macrophages were far less abundant in lesions (Fig. 4g). These data indicate that Msr1 contributes to the life cycle of proliferating macrophages in established atherosclerosis. Future work will need to elucidate whether the effect is direct or indirect, and investigate the mechanistic links between Msr1-mediated apoptosis, ER stress, and proliferation31,32.
The finding that local macrophage proliferation contributes substantially to lesional macrophage accumulation prompted us to test whether interference with proliferation can reduce established atherosclerosis. Apoe−/− HCD mice received the cell cycle inhibitor fluorouracil (5-FU). It is known that 5-FU decreases the production of monocytes33. However, the drug was delivered for only 4 weeks, a period of time in which monocytes contribute little to macrophage accumulation in established atherosclerosis. 5-FU significantly decreased the rate (Supplementary Fig. 6a) and number (Supplementary Fig. 6b) of proliferating aortic macrophages. The overall effect of 5-FU resulted in fewer Mac3+ macrophages and smaller lesions (Supplementary Fig. 6 c–e). These data are consistent with studies in which genetic disruption of tumor suppressor genes and cell cycle regulators promoted macrophage proliferation and increased atherosclerosis34,35. These findings demonstrate that cellular proliferation is a dominant feature of atherosclerotic development and a potent therapeutic target.
Atherosclerosis is a lipid-driven inflammatory disease characterized by monocyte recruitment and differentiation1. When lesions regress, monocyte recruitment is suppressed13. Our study builds on this paradigm by providing evidence that, in addition to monocyte recruitment and differentiation, monocyte-derived lesional macrophages proliferate. Atherosclerosis develops, our data indicate, via a multiphasic numerical escalation of the monocyte-macrophage lineage. Its sequence can be summarized as follows: (1) hematopoietic stem cells proliferate in the bone marrow and spleen and give rise to monocytes11,36,37; (2) Monocytes circulate, infiltrate, and differentiate to macrophages5–7,13; (3) Lesional macrophages proliferate and locally augment their numbers in plaques (Fig. 4h). The evidence for substantial local expansion of mononuclear phagocytes resulting from proliferation within the intimal lesion adds a new dimension to our understanding of lesional leukokinetics. Moving forward, it will be important to evaluate the importance of local macrophage proliferation in human atherosclerosis, and to determine how interfering with monocyte recruitment and macrophage proliferation at various stages of atherosclerosis affects plaque progression.
C57BL/6J (wild-type, WT), B6.SJL-PtprcaPep3b/BoyJ (CD45.1+), apolipoprotein E–deficient (Apoe−/−; B6.129P2-Apoetm1Unc), low density lipoprotein-deficient (Ldlr−/−; B6.129S7-Ldlrtm1Her/J) and macrophage scavenger receptor 1-deficient (Msr1−/−; B6.Cg-Msr1tm1Csk/J) mice were purchased from The Jackson Laboratories. Mice deficient in the β-subunit of the granulocyte-macrophage colony stimulating factor receptor (Csf2rb−/−) were kindly provided by Dr. Jeffrey Whitsett at Cincinnati Children’s Hospital Medical Center. Apoe−/−CD45.1+ were generated after backcrossing Apoe−/− mice to C57BL/6 CD45.1+. At 6–8 wk of age, Apoe−/− mice were placed on a “Western” diet (high cholesterol diet, HCD) (21.2% fat weight−1; 0.2% cholesterol) (Harlan Teklad, Madison, WI) or remained on a chow diet for durations listed in the manuscript. Ldlr−/− mice were fed a high fat/cholesterol diet (D12108C: 20% fat/weight; 1.25% cholesterol) (Research Diets Inc., New Brunswick, NJ). All mice were female except Ldlr−/−, which were male. All protocols were approved by the Institutional Animal Care and Use Committee (IACUC), Subcommittee on Research Animal Care (SRAC), Massachusetts General Hospital, Charlestown, MA.
BrdU incorporation studies: BrdU was administered using osmotic mini-pumps implanted subcutaneously (Alzet model 1002) at a dose of 50 μg day−1 or injected i.v. at 1mg mouse−1. Monocyte depletion: Mice were i.v. injected daily with 200 μl clodronate loaded liposomes. Clodronate was a gift from Roche and was incorporated into liposomes are described previously38. Parabiosis: The procedure, adapted from17 was conducted as previously described39. Briefly, after shaving the corresponding lateral aspects of each mouse, matching skin incisions were made from behind the ear to the tail of each mouse, and the subcutaneous fascia was bluntly dissected to create about 0.5 cm of free skin. The scapulas were sutured using a mono-nylon 5.0 (Ethicon, Albuquerque, NM), and the dorsal and ventral skins were approximated by continuous suture. Mice were joined for intervals of 4 to 5 weeks. In one set of experiments, after an interval of 5 weeks joined, parabiosed mice were surgically separated by a reversal of the procedure. Percent chimerism in the blood and aortic tissue was defined for either gated monocytes or macrophages as %CD45.1+ (%CD45.1+ & %CD45.2+)−1 in CD45.2+ mice, and as %CD45.2+ (%CD45.2+ & %CD45.1+)−1 in CD45.1+ mice. Bone marrow chimeras: Ldlr−/− HCD mice with established atherosclerosis were lethally irradiated (950cGy) and reconstituted with CD45.1+ wild type (WT) bone marrow. For generation of mixed chimeras naive Ldlr−/− mice were lethally irradiated and reconstituted with a 50:50 mix of bone marrow cells from CD45.1+ wild type mice and CD45.2+ knockouts for SR-A I/II (Msr1−/−) and the GM-CSF receptor β-chain (Csf2rb−/−) respectively. Adoptive transfer: Ly-6Chigh CD115+ monocytes were sorted from GFP+ mice. 3 × 106 cells were injected i.v. into Apoe−/− mice consuming HCD for 12 weeks. Treatment: Fluorouracil (5-FU) (APP Pharmaceuticals, LLC, USA) was administered via osmotic mini-pumps at a dose of 15 mg kg−1 per day for 4 weeks with two intermittent boluses of 100 mg kg−1 iv. Anti-GM-CSF antibody (functional grade MP1-22E9, eBioscience) was delivered i.v. at a dose of 100 μg (mouse day)−1.
Peripheral blood for flow cytometric analysis was collected by cardiac puncture, using a 50 mM EDTA solution as anticoagulant. Erythrocytes were lysed using BD FACS Lysing Solution (BD Biosciences). Total white blood cell count was determined by preparing a 1:10 dilution of (undiluted) peripheral blood obtained from the orbital sinus using heparin-coated capillary tubes in RBC Lysis Buffer (BioLegend). After organ harvest, single cell suspensions were obtained as follows: for bone marrow, femur and tibia of one leg were flushed with PBS. Spleens were homogenized through a 40 μm-nylon mesh, after which erythrocyte lysis was performed on the spleens using RBC Lysis Buffer (BioLegend). For aortic tissue, the entire aorta was digested (from the root to the iliac bifurcation) according to a method previously published40. The procedure involves perfusion of the aorta (20 ml PBS) prior to digestion. Aortic tissue was cut in small pieces and subjected to enzymatic digestion with 450 U ml−1 collagenase I, 125 U ml−1 collagenase XI, 60 U ml−1 DNase I and 60 U ml−1 hyaluronidase (Sigma-Aldrich, St. Louis, MO) for 1 h at 37 °C while shaking. Total viable cell numbers were obtained using Trypan Blue (Cellgro, Mediatech, Inc, VA). To separate intimal lesions from the media and adventitia we adapted the method previously described by Butcher et al27. In brief, aortas were cut open longitudinally and pinned onto black wax with the intimal area facing upwards. A thin film of enzymatic digestion mixture was applied directly onto the exposed intima. After 15 min of incubation at room temperature lesions were scraped off the underlying media with a glass coverslip. Lesional tissue and the remaining media and adventitia were cut into small pieces and separately digested for 40 min at 37 °C while shaking as described above. Tissue colony forming cell assay: To determine the number of myeloid colony-forming units, a single cell suspension was prepared from bone marrow, spleens and aortic tissue and 1×105 cells were plated in triplicates in complete methylcellulose medium (MethoCult GF M3434, Stemcell Technologies). Counts were performed after 8 d of culture. At least three independent samples per group were analyzed.
The following antibodies were used for flow cytometric analyses: anti-CD90.2-PE, 53–2.1 (BD Biosciences); anti-B220-PE, RA3-6B2 (BD Biosciences); anti-CD49b-PE, DX5 (BD Biosciences); anti-NK1.1-PE, PK136 (BD Biosciences); anti-Ly-6G-PE, 1A8 (BD Biosciences); anti-TER119-PE, TER119 (BD Biosciences); anti-CD11b-APCcy7, M1/70 (BD Biosciences); anti-CD11c-Alexa Fluor 700, HL3 (BD Biosciences); anti-IAb-Percp Cy5.5, AF6-120.1 (BD Biosciences); anti-F480-PE-Cy7, BM8 (BioLegend); anti-CD45.2-FITC, 104 (BD Biosciences); anti-CD45.1-APC, A20 (BD Biosciences); anti-CD115-APC, AFS98 (ebioscience). Antibody dilutions were 1:300 – 1:700. Cell cycle analysis was carried out using FxCycle violet stain (Invitrogen). Contribution of newly-made cells to different cell populations was determined by in vivo labeling with bromodeoxyuridine (BrdU) (BD Biosciences). Incorporation was measured using either FITC or APC-conjugated anti-BrdU antibodies according to the manufacturer’s instructions. Monocytes and macrophages were identified similarly as described previously39. Specifically, monocytes were identified as CD11bhi Lin− (Lin = CD90/B220/CD49b/NK1.1/Ly-6G/Ter119) F480lo. Macrophages were identified as CD11bhi Linlo F480hi CD11clo-neg. Data were acquired on an LSRII (BD Biosciences) and analyzed with FlowJo v8.8.6 (Tree Star, Inc.). The ImageStreamX™ imaging flow cytometry platform was used to analyze the cell cycle as per manufacturer’s instructions.
Atherosclerotic plaque specimens were obtained from patients undergoing carotid endarterectomies. Carotid tissue was obtained from cardiac transplants by protocols approved by the Human Investigation Review Committee at the Brigham and Women’s Hospital. Specimens were immediately immersed in saline solution, transported to the laboratory on ice (within 1 hr), embedded in OCT compound, and stored at −80°C freezer until use. Serial cryostat sections (5 μm) are cut, air dried onto microscope slides (Fisher Scientific, Pittsburgh, PA) and used for immunohistochemistry. Mouse aortae were excised, embedded in O.C.T. compound (Sakura Finetek), and flash-frozen in isopentane and dry ice. Aortic roots were sectioned into 5 um slices, generating ~30–40 sections that spanned the entirety of the aortic root. For comparison of lesion size between the groups, sections that captured the maximum lesion area were used. Immunofluorescence double staining was carried out using BrdU Flow Kits (BD Biosciences), Mac-3: clone M3/84 (BD Biosciences) and FITC-Ki67: clone SP6 (Abcam). For BrdU immunofluorescence double staining, the sections were stained with Mac-3 antibody followed by a biotinylated secondary antibody and streptavidin-Texas Red (GE Healthcare). To denature DNA, the sections were incubated with 2 N HCl for 10 min at room temperature and for 20 min at 37 °C. Acid neutralization was achieved by immersing sections in 0.1M borate buffer. Cover slips were placed over specimens using mounting medium containing DAPI (Vector Laboratories) to identify cell nuclei. Images capture was performed using an epifluorescence microscope (Nikon Eclipse 80i, Nikon Instruments Inc.) equipped with a Cascade Model 512B camera (Roper Scientific). For immunohistochemistry, anti-CD45.1: clone A20 (eBioscience), anti-CD45.2: clone 104 (BioLegend), anti-Mac-3: clone M3/84 (BD Biosciences) was used for mouse aortic root sections, and anti-Ki67 (abcam), anti-CD68: clone KP1 (Dako) were used to stain human carotid arteries. In order to block endogenous peroxidase activity, tissue sections were pre-treated with 0.3% hydrogen peroxide solution. Following application of the appropriate biotinylated secondary antibodies, samples were developed using the Vectastain ABC kit (Vector Laboratories) and either AEC (DakoCytomation) or DAB (Vector Laboratories) substrates. Sections were counterstained with Harris Hematoxylin and specificity of staining was confirmed using relevant isotype controls. Masson trichrome (Sigma) and Oil Red O (Sigma) staining were performed to visualize collagen and lipid content, respectively. Hematoxylin and eosin (H&E) staining was performed to assess overall tissue morphology. Images were digitized using a Nanozoomer 2.0RS (Hamamatsu).
Results were expressed as mean ± SEM. Statistical tests included unpaired Student’s t test using Welch’s correction for unequal variances and 1-way ANOVA followed by Tukey’s or Newman-Keuls Multiple Comparison Test. P values of 0.05 or less were considered to denote significance.
The authors thank M. Greene for secretarial assistance. This work was supported in part by US National Institutes of Health grants 1R01HL095612 (to F.K.S.) and HHSN 268201000044C, P01-A154904, U24-CA092782, P50-CA086355 (to R.W.), and start-up funding provided by the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research and the Department of Laboratory Medicine and Pathobiology, University of Toronto (to C.S.R.). C.S.R. was supported by the MGH Executive Committee on Research (ECOR) Postdoctoral Award. G.F.W. and I.H. were supported by the German Research Foundation. I. T. was supported by the Max Kade Foundation. L.M.S.G. was supported by the Boehringer Ingelheim Funds.
Authors contributionsC.S.R. and I.H. conceived the project, designed and performed experiments, analyzed and interpreted data. G.F.W., I.T., L.M.S.G, D.S., C.J.Z., E.A.S performed experiments and helped to interpret the data; J.L.F., R.G., I.H. performed animal surgeries; Y.I. performed the immunofluorescence histology and immunohistochemistry; M.P. performed ImageStreamX™ Mark II studies; G.K.S., P.L., M.N., M.H. and R.W. provided materials, intellectual input, and edited the manuscript; N.v.R. provided clodronate liposomes; H.Y.L. edited the manuscript. F.K.S. conceived the project, designed experiments, and supervised the study. C.S.R. and F.K.S. wrote the manuscript.
The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to F.K.S. (ude.dravrah.hgm@iksriwsf), Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Simches Research Building, 185 Cambridge St., Boston, MA 02114; phone, 617-724-6242, fax, 617-643-6133 or C.S.R. (email@example.com), Division of Advanced Diagnostics, Toronto General Research Institute, University Health Network, Toronto Medical Discovery Tower, 101 College St., Toronto, ON M5G1L7; phone, 416-581-7510.